Is Milrinone Effective for Infants with Mild-to-Moderate Congenital Diaphragmatic Hernia?Funding None.
06 August 2018
20 December 2018
01 February 2019 (online)
Objective Pulmonary hypertension with left ventricular dysfunction commonly occurs in congenital diaphragmatic hernia (CDH). Milrinone, a phosphodiesterase-III inhibitor with lusitropic and vasodilator effects, is used in up to 30% of CDH infants across the United States. No randomized trials have tested the efficacy or safety of milrinone in CDH neonates.
Study Design We performed a paired retrospective analysis of CDH infants to assess the efficacy of milrinone treatment (N = 24 pairs). Efficacy was assessed by change in oxygenation index (OI) and calculated pulmonary artery pressure (PAP). We evaluated safety on the basis of risks factors such as nonoperative bleeding, dysrhythmia, hypokalemia, and thrombocytopenia.
Results The median age of milrinone initiation was 18 hours (interquartile range [IQR]: 9–38) and the median duration was 127 hours (IQR: 95–194). PAP did not change from the baseline of 49 ± 11 mm Hg (milrinone) and 53 ± 11 mm Hg (no milrinone; p = 0.327). Baseline OI was 9.6 ± 6.5. There was a similar decrease in OI (median [IQR]; milrinone: 58% [16–74]; vs. no milrinone: 65% [50–71]; p = 0.221 between groups; p < 0.005 within groups). Baseline left ventricle measurements were similar. Both groups showed significant improvement over time. No adverse events were noted.
Conclusion In OI-matched untreated neonates with mild-to-moderate CDH, milrinone use was associated with neither improved OI, PAP, or left ventricular measurements, nor adverse events. Study limitations warrant prospective randomized controlled trials.
B.A.Y. and M.M. contributed to the conception and design of the study, data collection and analysis, and manuscript preparation; M.Y. contributed to data analysis and manuscript preparation. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
- 1 McGivern MR, Best KE, Rankin J. , et al. Epidemiology of congenital diaphragmatic hernia in Europe: a register-based study. Arch Dis Child Fetal Neonatal Ed 2015; 100 (02) F137-F144
- 2 Leeuwen L, Fitzgerald DA. Congenital diaphragmatic hernia. J Paediatr Child Health 2014; 50 (09) 667-673
- 3 Malowitz JR, Hornik CP, Laughon MM. , et al. Management practice and mortality for infants with congenital diaphragmatic hernia. Am J Perinatol 2015; 32 (09) 887-894
- 4 Kinsella JP, Steinhorn RH, Mullen MP, Hopper RK, Keller RL, Ivy DD. ; Pediatric Pulmonary Hypertension Network (PPHNet). The left ventricle in congenital diaphragmatic hernia: Implications for the management of pulmonary hypertension. J Pediatr 2018; (197) 17-22
- 5 Hagadorn JI, Brownell EA, Herbst KW, Trzaski JM, Neff S, Campbell BT. Trends in treatment and in-hospital mortality for neonates with congenital diaphragmatic hernia. J Perinatol 2015; 35 (09) 748-754
- 6 Zalla JM, Stoddard GJ, Yoder BA. Improved mortality rate for congenital diaphragmatic hernia in the modern era of management: 15 year experience in a single institution. J Pediatr Surg 2015; 50 (04) 524-527
- 7 Patel N. Use of milrinone to treat cardiac dysfunction in infants with pulmonary hypertension secondary to congenital diaphragmatic hernia: a review of six patients. Neonatology 2012; 102 (02) 130-136
- 8 Kumar VHS, Dadiz R, Koumoundouros J, Guilford S, Lakshminrusimha S. Response to pulmonary vasodilators in infants with congenital diaphragmatic hernia. Pediatr Surg Int 2018; 34 (07) 735-742
- 9 Galiè N, Hoeper MM, Humbert M. , et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30 (20) 2493-2537
- 10 Samiee-Zafarghandy S, Raman SR, van den Anker JN. , et al; Best Pharmaceuticals for Children Act—Pediatric Trials Network Administrative Core Committee. Safety of milrinone use in neonatal intensive care units. Early Hum Dev 2015; 91 (01) 31-35
- 11 Gaies MG, Gurney JG, Yen AH. , et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med 2010; 11 (02) 234-238
- 12 Axelsson B, Häggmark S, Svenmarker S. , et al. Effects of combined milrinone and levosimendan treatment on systolic and diastolic function during post-ischemic myocardial dysfunction in a porcine model. J Cardiovasc Pharmacol Ther 2016; 21 (05) 495-503
- 13 Zausig YA, Stowe DF, Zink W, Grube C, Martin E, Graf BM. A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts. Anesth Analg 2006; 102 (06) 1646-1652
- 14 Bassler D, Choong K, McNamara P, Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol Neonate 2006; 89 (01) 1-5
- 15 McNamara PJ, Shivananda SP, Sahni M, Freeman D, Taddio A. Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. Pediatr Crit Care Med 2013; 14 (01) 74-84
- 16 Burkhardt BE, Rücker G, Stiller B. Prophylactic milrinone for the prevention of low cardiac output syndrome and mortality in children undergoing surgery for congenital heart disease. Cochrane Database Syst Rev 2015; (03) CD009515
- 17 Lakshminrusimha S, Keszler M, Kirpalani H. , et al for the NICHD Neonatal Research Network. Milrinone in congenital diaphragmatic hernia - a randomized pilot trial: study protocol, review of literature and survey of current practices. Matern Health Neonatol Perinatol 2017; 3: 27
- 18 El-Khuffash A, McNamara PJ, Breatnach C. , et al. The use of milrinone in neonates with persistent pulmonary hypertension of the newborn - a randomised controlled trial pilot study (MINT 1): study protocol and review of literature. Matern Health Neonatol Perinatol 2018; 4: 24